News
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...
The Dow Dow Jones Industrial Average was most recently trading 492 points higher (1.1%), as shares of Amgen Amgen Inc. and Merck Merck & Co. Inc. have contributed around 25% of the blue-chip gauge's ...
Buoyed by positive gains for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday morning. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...
Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.
17h
Clinical Trials Arena on MSNAmgen and Zai Lab’s trial of gastric cancer therapy meets primary endpointAmgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...
Detroit Lions legend Barry Sanders has let a terrifying personal experience guide him to advocate for a very important cause ...
Mirae Asset Global Investments trimmed its Amgen holdings by 1.5% in the first quarter, selling 7,398 shares. This reduction ...
Thanks to his trusty Dexcom continuous glucose monitor (CGM), former boy band star Lance Bass is saying “bye bye bye” to ...
In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...
New study details gaps between actual and recommended use of statins and other lipid-lowering drugs—and estimates public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results